© 1996 by Oxford University Press
Journal of the National Cancer Institute, Vol. 88, No. 20, 1483-1488,
October 16, 1996
© 1996 Oxford University Press
Prediction of Relapse of Pediatric Acute Myeloid Leukemia by Use of Multidimensional Flow Cytometry
Division of Pediatric Oncology, Fred Hutchinson Cancer Research Center Seattle, WA Division of Pediatric Hematology/Oncology, University of Washington, Seattle and Childrens Cancer Group Arcadia, CA
Division of Oncology, Children's Hospital of Philadelphia PA Childrens Cancer Group
Department of Preventive Medicine, University of Southern California Los Angeles Childrens Cancer Group
Division of Pediatric Hematology/Oncology, Indiana University Indianapolis Childrens Cancer Group
Hematologics, Inc. Seattle, WA
Cytometry Associates, Inc. Brentwood, TN
Correspondence to: Eric L. Sievers, M.D., Division of Pediatric Oncology, Fred Hutchinson Cancer Research Center, 1124 Columbia St., Seattle, WA 98104
BACKGROUND:: Most patients receiving therapy for acute myeloid leukemia (AML) enter an interval in which leukemic blast cells cannot be detected by light microscopy (i.e., morphologic remission). However, many of these patients experience a subsequent relapse. Multidimensional flow cytometry, which allows the discrimination of antigens expressed on normal and malignant cells, can detect small numbers of cancer cells in bone marrow or peripheral blood specimens. This technique enables the detection of one leukemic blast cell among 103 to 102 normal regenerating hematopoietic cells.
PURPOSE:: We determined whether the presence of residual leukemic blast cells, identified in the bone marrow of pediatric patients with AML by use of multidimensional flow cytometry, would be predictive of subsequent leukemic relapse.
METHODS:: Multidimensional flow cytometry was performed on 205 marrow specimens collected throughout the course of treatment from 39 patients who had achieved morphologic remission. The analyses employed monoclonal antibodies directed against CD45 in combination with mixed pairs of monoclonal antibodies directed against 10 other antigens. A time-varying Cox regression analysis that controlled for sample time intervals, age, sex, morphologic classification of disease, and white blood cell count at diagnosis was used to relate the multidimensional flow cytometric results to the risk of relapse after achieving remission. Reported P values are two-sided.
RESULTS:: Thirty-five of the 39 patients had bone marrow specimens available from the time that first morphologic remission was achieved. Leukemic blast cells were detected in the specimens from 19 (54%) of these 35 patients. Twenty-five of the 35 patients did not receive an allogeneic (i.e., from a different genetic background) bone marrow transplant during first morphologic remission, and 13 of 14 with residual leukemic cells experienced a relapse at a median time of 153 days after diagnosis (range, 48–863 days). Nine of the 11 patients who did not receive an allogeneic bone marrow transplant and lacked evidence of leukemic blast cells at first morphologic remission relapsed at a median time of 413 days after diagnosis (range, 321–794 days). Among the 10 individuals who received an allogeneic bone marrow transplant during first morphologic remission, five were positive for leukemic blast cells and five were negative; one of these patients (positive for leukemic blast cells) experienced a relapse 265 days after diagnosis, and three others died of transplant-related complications. The estimated risk of relapse during intervals of multidimensional flow cytometric positivity (i.e., intervals of remission for which the immediately preceding cytometry measurement was positive) was 2.8 times greater than that during negative intervals (95% confidence interval = 1.1–7.0; P = .02).
CONCLUSIONS AND IMPLICATIONS:: Multidimensional flow cytometry identifies residual leukemia in more than half of the patients with AML who are in morphologic remission. The detection of leukemic blast cells in these patients by multidimensional flow cytometry is predictive of a more rapid relapse.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Al-Mawali, D. Gillis, and I. Lewis The Role of Multiparameter Flow Cytometry for Detection of Minimal Residual Disease in Acute Myeloid Leukemia Am J Clin Pathol, January 1, 2009; 131(1): 16 - 26. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. L. Scott, D. A. Wells, M. R. Loken, D. Myerson, W. M. Leisenring, and H. J. Deeg Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome Blood, October 1, 2008; 112(7): 2681 - 2686. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. N. Mandrell and M. Pritchard Understanding the Clinical Implications of Minimal Residual Disease in Childhood Leukemia Journal of Pediatric Oncology Nursing, January 1, 2006; 23(1): 38 - 44. [Abstract] [PDF]
|
|
|
|
|
|
D. A. Wells, M. Benesch, M. R. Loken, C. Vallejo, D. Myerson, W. M. Leisenring, and H. J. Deeg Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation Blood, July 1, 2003; 102(1): 394 - 403. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. L. Sievers, B. J. Lange, T. A. Alonzo, R. B. Gerbing, I. D. Bernstein, F. O. Smith, R. J. Arceci, W. G. Woods, and M. R. Loken Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia Blood, May 1, 2003; 101(9): 3398 - 3406. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. J. Deeg, B. Storer, J. T. Slattery, C. Anasetti, K. C. Doney, J. A. Hansen, H.-P. Kiem, P. J. Martin, E. Petersdorf, J. P. Radich, et al. Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome Blood, July 30, 2002; 100(4): 1201 - 1207. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Y. Zang, R. G. Goodwin, M. R. Loken, E. Bryant, and H. J. Deeg Expression of tumor necrosis factor-related apoptosis-inducing ligand, Apo2L, and its receptors in myelodysplastic syndrome: effects on in vitro hemopoiesis Blood, November 15, 2001; 98(10): 3058 - 3065. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. F. San Miguel, M. B. Vidriales, C. Lopez-Berges, J. Diaz-Mediavilla, N. Gutierrez, C. Canizo, F. Ramos, M. J. Calmuntia, J. J. Perez, M. Gonzalez, et al. Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification Blood, September 15, 2001; 98(6): 1746 - 1751. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. J. Deeg, H. M. Shulman, J. E. Anderson, E. M. Bryant, T. A. Gooley, J. T. Slattery, C. Anasetti, A. Fefer, R. Storb, and F. R. Appelbaum Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age Blood, February 15, 2000; 95(4): 1188 - 1194. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.F. San Miguel, A. Martinez, A. Macedo, M.B. Vidriales, C. Lopez-Berges, M. Gonzalez, D. Caballero, M.A. Garcia-Marcos, F. Ramos, J. Fernandez-Calvo, et al. Immunophenotyping Investigation of Minimal Residual Disease Is a Useful Approach for Predicting Relapse in Acute Myeloid Leukemia Patients Blood, September 15, 1997; 90(6): 2465 - 2470. [Abstract] [Full Text] [PDF]
|
|